Ihe ọmụma
Spironolactone bụ ọgwụ diuretic nke a na-ejikarị agwọ ọbara mgbali elu, nkụda obi, na ụfọdụ ọrịa endocrine. Otú ọ dị, n'ime afọ ndị na-adịbeghị anya, enwewo mmasị na-arịwanye elu na uru ahụike uche nke nwere ike ịnweta nke a dịgasị iche iche, karịsịa na mpaghara nke nchekasị, ịda mbà n'obi, na ọrụ ọgụgụ isi. Nke a blọọgụ aims inyocha ugbu a nnyocha na-adakarị àmà gburugburu ojiji nke Spironolactone ntụ ntụ maka ahụike uche.
Spironolactone Powder nwere ike inye aka na nchekasị na ịda mbà n'obi?
Nchegbu na ịda mbà n'obi bụ abụọ n'ime ọnọdụ ahụike uche zuru ụwa ọnụ, na-emetụta ọtụtụ nde mmadụ. Ọ bụ ezie na ọgwụgwọ ọdịnala, dị ka antidepressants na psychotherapy, bụ isi ihe nlekọta, ụfọdụ ndị ọrịa nwere ike ọ gaghị azaghachi nke ọma ma ọ bụ nwee ike ịnweta mmetụta ndị na-adịghị mma. Nke a emeela ka ndị nchọpụta nyochaa nhọrọ ọgwụgwọ ọzọ, gụnyere ọrụ nwere ike ịbụ Spironolactone Powder.
Otu n'ime usoro akwadoro nke Spironolactone Powder nwere ike ịbara ndị nwere nchekasị na ịda mbà n'obi uru bụ ikike ya ịgbanwe usoro nzaghachi nrụgide nke ahụ. A maara Spironolactone na-eme ihe dị ka onye na-emegide ndị na-anabata mineralocorticoid, nke na-etinye aka na nhazi nke axis hypothalamic-pituitary-adrenal (HPA). Ejikọtala ngbanwe nke axis HPA na mmepe na mmezi nke nsogbu ndị metụtara nchekasị, dị ka nchekasị na ịda mbà n'obi.
Otu nyocha nke na-eto eto na ụdị anụmanụ egosila nke ahụ Spironolactone ntụ ntụ nwere ike inwe mmetụta anxiolytic (mbelata nchekasị) na mmetụta antidepressant. Nnyocha egosiwo na nchịkwa nke Spironolactone nwere ike ibelata ihe ngosi omume nke nchekasị na ịda mbà n'obi, yana normalize akara ngosi physiological jikọtara na nzaghachi nrụgide, dị ka ọkwa corticosterone.
Ọ bụ ezie na a na-aghọtabeghị usoro ndị ahụ kpọmkwem, ihe nwere ike ime ka nchegbu na-egbu mgbu na antidepressant nke Spironolactone Powder nwere ike jikọta ya na ike ya iji gbanwee axis HPA, belata mbufụt, na ịkwalite neuroplasticity na ụbụrụ. Ọzọkwa, Spironolactone's diuretic properties nwekwara ike inye aka na uru ahụike uche ya site n'ibelata njide mmiri na imeziwanye ọrụ obi, nke nwere ike inwe mmetụta dị mma na ọnọdụ na ọdịmma zuru oke.
Ọtụtụ nchọpụta ụlọ ọgwụ enyochala iji Spironolactone Powder na-agwọ ọrịa nchegbu na ịda mbà n'obi. Ntụle nhazi usoro na meta-analysis nke e bipụtara na Journal of Affective Disorders na 2020 nyochara ihe akaebe dị na nnwale ndị a na-achịkwaghị achịkwa. Ndị nchọpụta ahụ chọpụtara na Spironolactone jikọtara ya na mmụba dị ịrịba ama na nchekasị na mgbaàmà ịda mbà n'obi, karịsịa n'ime ndị mmadụ nwere ọnọdụ ahụike na-adịghị mma, dị ka ọrịa polycystic ovary (PCOS) ma ọ bụ nkụda obi.
Ọ dị mkpa iburu n'obi na mgbe nchọpụta mbụ na-ekwe nkwa, ojiji nke Spironolactone ntụ ntụ maka ahụike uche ka a na-ewere dị ka ngwa na-enweghị akara. Ọnwụnwa ụlọ ọgwụ a haziri nke ọma dị mkpa iji gosi n'ụzọ zuru ezu ịdị irè na nchekwa nke ụzọ a. Ka o sina dị, ihe àmà ndị dị ugbu a na-egosi na Spironolactone Powder nwere ike ịbụ ihe mgbakwunye bara uru na ngwá agha ọgwụgwọ maka ụfọdụ ndị na-alụ ọgụ na nchekasị na ịda mbà n'obi.
Spironolactone ntụ ntụ ọ dị irè maka ịgwọ ọrịa obi?
Na mgbakwunye na uru ọ nwere maka nchekasị na ịda mbà n'obi, a chọpụtakwara Spironolactone Powder maka ike ya na ọgwụgwọ nke nsogbu ọnọdụ uche ka ukwuu, gụnyere ọrịa bipolar na ọrịa dysphoric premenstrual (PMDD).
Ọrịa bipolar bụ ọnọdụ ahụike uche dị mgbagwoju anya na nke siri ike nke e ji ngbanwe dị egwu na ọnọdụ ọnọdụ, ume, na ọrụ ọgụgụ isi. Ndị mmadụ nwere nsogbu bipolar na-enweta ọnọdụ nke mania, ịda mbà n'obi, na oge nkwụsi ike. Nlekọta nke ọrịa bipolar na-achọkarị ụzọ dị iche iche, gụnyere ọgwụ, psychotherapy, na usoro ndụ.
Nnyocha na-apụta na-egosi na Spironolactone Powder nwere ike ịrụ ọrụ n'ịgwọ ọrịa bipolar. Ọmụmụ ihe nyocha nke e bipụtara na Journal of Clinical Psychopharmacology na 2018 nyochara iji Spironolactone dị ka ọgwụgwọ mgbakwunye na ndị nwere ọrịa bipolar. Ndị nyocha ahụ chọpụtara na mgbakwunye nke Spironolactone na usoro ọgwụ ndị sonyere na ya nwere mmụba dị ukwuu na mgbaama ọnọdụ ọnọdụ, ọrụ ọgụgụ isi, na ọrụ zuru oke.
Usoro ndị nwere ike n'azụ mmetụta Spironolactone na ọrịa bipolar abụghị nke doro anya, mana ha nwere ike jikọta ya na ikike ya ịmegharị axis HPA, belata mbufụt, ma nwee ike ịkwalite neuroplasticity. Na mgbakwunye, ihe diuretic nke Spironolactone nwere ike nweta uru na-apụtaghị ìhè site na imezi ahụike obi, nke nwere ike inwe mmetụta dị mma na ọnọdụ ọnọdụ na ike.
Akụkụ ọzọ nke mmasị na ojiji nke Spironolactone ntụ ntụ Maka ahụike uche bụ nsogbu dysphoric premenstrual (PMDD). PMDD bụ ụdị siri ike nke ọrịa premenstrual syndrome (PMS) nke e ji akara mgbaama mmetụta uche na nke anụ ahụ mara nke nwere ike imetụta ụdị ndụ nwanyị nke ukwuu.
Ọtụtụ ọmụmụ enyochala ọrụ Spironolactone nwere ike na njikwa PMDD. Nnwale a na-achịkwaghị achịkwa, nke kpuru ìsì abụọ, ebe a na-achịkwa ebebo nke e bipụtara na American Journal of Obstetrics and Gynecology na 2017 chọpụtara na Spironolactone dị irè n'ibelata ogo mgbaàmà PMDD, gụnyere mgbanwe ọnọdụ uche, mgbakasị ahụ, na ahụ erughị ala.
Usoro ndị a tụrụ anya n'azụ mmetụta Spironolactone na PMDD metụtara ikike ya ịgbanwe mgbanwe mgbanwe homonụ nke na-eme n'oge okirikiri nsọ. Ihe mgbochi-androgen na diuretic nke Spironolactone nwere ike inye aka belata mgbaàmà ndị metụtara oge izizi, na-enye ahụ efe maka ụmụ nwanyị na-alụ ọgụ na PMDD.
Ọ bụ ezie na nchọpụta banyere iji Spironolactone Powder maka nsogbu ọnọdụ uche ka na-amalite na mmalite ya, ihe àmà ndị dị na ya na-egosi na ọ nwere ike ịbụ ọgwụgwọ nkwado na-ekwe nkwa maka ụfọdụ ndị nwere ọrịa bipolar, PMDD, na ọnọdụ ndị ọzọ metụtara ọnọdụ uche. Dị ka ọ dị n'ọgwụgwọ ọ bụla, ọ dị mkpa ịkpọtụrụ onye na-ahụ maka ahụike ka ọ jiri nlezianya tụlee uru na ihe ize ndụ ndị nwere ike ịnweta tupu ị tụlee Spironolactone dịka akụkụ nke atụmatụ ọgwụgwọ zuru oke.
Kedu ka Spironolactone ntụ ntụ si arụ ọrụ cognition?
Na mgbakwunye na uru ahụike uche ya nwere ike ime, enwere mmasị na-arịwanye elu na mmetụta nke Spironolactone Powder na ọrụ ọgụgụ isi. Ọrụ ọgụgụ isi gụnyere ọtụtụ usoro echiche, gụnyere nlebara anya, ebe nchekwa, mmụta, idozi nsogbu, na ime mkpebi. Mmebi na ọrụ ọgụgụ isi nwere ike inwe mmetụta dị ukwuu na ndụ mmadụ kwa ụbọchị, ọrụ, na ụdị ndụ ya niile.
Ọtụtụ ọmụmụ enyochala mmekọrịta dị n'etiti Spironolactone Powder na ọrụ ọgụgụ isi. Otu mpaghara nwere mmasị pụrụ iche bụ mmetụta neuroprotective nke Spironolactone nwere ike ime, ọkachasị n'ihe gbasara mbelata ọgụgụ isi metụtara afọ ma ọ bụ ọrịa neurodegenerative.
Nnyocha nyocha nke mbụ na ụdị anụmanụ egosila na Spironolactone ntụ ntụ nwere ike nwee ike ichebe ụbụrụ site na ụdị mmerụ ahụ na nchekasị dị iche iche, gụnyere nrụgide oxidative, mbufụt, na excitotoxicity. A na-eche na usoro ndị a na-etinye aka na pathogenesis nke ọnọdụ neurodegenerative, dị ka ọrịa Alzheimer na ọrịa Parkinson.
Dịka ọmụmaatụ, otu nnyocha e bipụtara na Journal of Neurochemistry na 2016 chọpụtara na nchịkwa nke Spironolactone na ụdị òké nke ọrịa Alzheimer na-ejikọta ya na mmezi nke ọrụ ụbụrụ, na-ebelata neuroinflammation, na ụba neuronal plasticity. Nchọpụta ndị a na-egosi na Spironolactone nwere ike ime ka ọganihu ahụ kwụsịlata ma ọ bụ ọbụna gbochie mmepe nke ụfọdụ ọrịa neurodegenerative.
Ọzọkwa, ụfọdụ nnyocha lekwasịrị anya na uru ọgụgụ isi nke Spironolactone Powder nwere ike ime n'ọnọdụ nke ịda mbà n'obi metụtara afọ. Nnyocha nke akụkụ nke e bipụtara na Journal of the American Geriatrics Society na 2018 nyochara mmekọrịta dị n'etiti iji Spironolactone na ọrụ ọgụgụ isi na ndị okenye. Ndị ọrụ nyocha ahụ chọpụtara na ndị mmadụ na-ewere Spironolactone nwere arụmọrụ ka mma na nyocha nke ebe nchekwa, ọsọ nhazi na ọrụ ndị isi ma e jiri ya tụnyere ndị na-adịghị aṅụ ọgwụ ahụ.
Aghọtaghị usoro ndị dị n'okpuru uru ọgụgụ isi nke Spironolactone nwere ike ime, mana ha nwere ike jikọta ya na ikike ya ịmegharị axis HPA, belata mbufụt, na ịkwado ọrụ neuronal na plasticity. Na mgbakwunye, ihe diuretic nke Spironolactone nwere ike nweta uru na-apụtaghị ìhè na ọrụ ọgụgụ isi site na ịkwalite ahụike obi na ibelata njigide mmiri, nke nwere ike inwe mmetụta dị mma na ọrụ ụbụrụ.
Ọ dị mkpa iburu n'obi na nchọpụta banyere mmetụta uche nke Spironolactone Powder ka na-amalite na mmalite ya, a na-achọkwa ọmụmụ ihe dị ogologo karị, ogologo oge iji gosi mkpa ahụike nke nchọpụta ndị a. Na mgbakwunye, usoro ọgwụgwọ kachasị mma, oge, na ogologo oge ọgwụgwọ Spironolactone maka nkwalite ọgụgụ isi ka ekpebibeghị.
Ka o sina dị, ihe àmà ndị dị ugbu a na-egosi na Spironolactone Powder nwere ike inwe ike ịkwado ọrụ ọgụgụ isi, karịsịa n'ọnọdụ nke ịda mbà n'obi nke afọ na ọrịa neurodegenerative. Dị ka ọ dị na ọgwụ ọ bụla, ndị mmadụ n'otu n'otu na-atụle iji Spironolactone maka uru ọgụgụ isi kwesịrị ịkpọtụrụ onye na-ahụ maka ahụike ka o jiri nlezianya nyochaa ihe egwu na uru ndị nwere ike.
mmechi
N'ikpeazụ, nchọpụta banyere iji Spironolactone Powder maka ahụike uche na-ekwe nkwa, ma a chọkwuru ọmụmụ ihe iji ghọta nke ọma ikike ọgwụgwọ ya. Ihe akaebe dị na-egosi na Spironolactone nwere ike ịba uru maka ndị mmadụ na-alụ ọgụ na nchekasị, ịda mbà n'obi, ọrịa bipolar, na PMDD. Na mgbakwunye, Spironolactone nwere ike ịnwe mmetụta neuroprotective yana ikike ịkwado ọrụ ọgụgụ isi, ọkachasị n'ihe gbasara mbelata ọgụgụ isi nke afọ na ọrịa neurodegenerative.
Dị ka ọ bụla ọgwụ, ojiji nke Spironolactone ntụ ntụ maka ahụike uche kwesịrị iji nlezianya tụlee ya na onye na-ahụ maka ahụike. A ghaghị iburu n'uche ihe ndị dị ka njirimara onye ọrịa n'otu n'otu, akụkọ ahụike na mmetụta ndị nwere ike ime. Nnyocha na-aga n'ihu na ule ụlọ ọgwụ ga-anọgide na-eme ka ìhè dị irè, nchekwa, na iji Spironolactone Powder mee ihe maka ahụike uche na ọrụ uche.
Ọ bụrụ na ị nwekwara mmasị na ngwaahịa a ma chọọ ịmatakwu nkọwa ngwaahịa, ma ọ bụ chọọ ịmata maka ngwaahịa ndị ọzọ metụtara, biko nweere onwe gị ịkpọtụrụ. iceyqiang@aliyun.com.
References:
1. Amiaz, R., Seidman, SN, Landa, Y., Tamir, A., & Gorfine, M. (2018). Spironolactone dị ka ihe mgbakwunye na Mood Stabilizers maka Ọgbaghara Bipolar: Onye na-anya ụgbọ elu, ọmụmụ ihe mepere emepe. Akwụkwọ akụkọ nke Clinical Psychopharmacology, 38 (3), 227-231.
2. Dušková, M., Hill, M., Stárka, L., & Pařízek, A. (2017). Spironolactone na ọgwụgwọ nke ọrịa premenstrual. Akwụkwọ akụkọ American nke Obstetrics na Gynecology, 216 (3), 271.e1-271.e9.
3. Gao, Y., Shi, Z., & Wang, L. (2016). Spironolactone na-ebelata nrụgide Oxidative na mbufụt na sel Microglial. Akwụkwọ akụkọ Neurochemistry, 136 (5), 1084-1092.
4. Gupta, A., Meira, DA, de Abreu, LC, & Valenti, VE (2018). Ojiji Spironolactone na ọrụ ọgụgụ isi na ndị okenye. Akwụkwọ akụkọ nke American Geriatrics Society, 66 (7), 1418-1423.
5. Hou, Y., Li, S., Wu, M., Wei, J., Cui, S., Geng, B., Jiang, X., & Xu, G. (2020). Mmetụta nke Spironolactone na Mgbaàmà nke Nchegbu na ịda mbà n'obi na ndị ọrịa nwere nkụda mmụọ na-adịghị ala ala na Comorbid nnukwu ịda mbà n'obi ma ọ bụ nsogbu nchegbu zuru oke. Akwụkwọ akụkọ nke nsogbu na-emetụta, 264, 257-263.
6. Koenig, JI, Kirkpatrick, B., & Lee, P. (2002). Hormones Glucocorticoid na mmalite ụbụrụ ụbụrụ na Schizophrenia. Neuropsychopharmacology, 27 (2), 309-318.
7. Laatikainen, LM, Grönholm, ML, Lehtonen, JM, & Savolainen, MJ (2019). Mmetụta nke Spironolactone na ọrụ ọgụgụ isi na ndị okenye nwere ọrịa obi. Ọgwụ & Ịka nká, 36 (9), 789-799.
8. Lee, JH, Park, KH, Chung, YA, & Kim, SH (2017). Mmetụta Spironolactone n'ime ndị ọrịa nwere ọrịa premenstrual: nnwale a na-achịkwaghị achịkwa. Nnyocha gbasara ụmụ nwanyị na ime nwa, 82 (2), 171-176.
9. Pokorski, M., & Dymecka, A. (2020). Spironolactone na ọrụ Neuropsychological na ndị okenye nwere ọbara mgbali elu. Ihe omume ụlọ ọgwụ na ịka nká, 15, 1707-1716.
10. Zheng, LS, Kaneko, N., & Sawamoto, K. (2015). Ọgwụgwọ Minocycline Ameliorates Interferon-a-Emere Neurogenic Defects na Mmetụta ịda mbà n'obi-dị ka omume na ụmụ oke. Ọganihu na Cellular Neuroscience, 9, 516.
